Corbus Pharma announces FDA alignment for CRB-701 accelerated path; CMO resigns

Corbus Pharmaceuticals Holdings, Inc.

FDA agreed on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, with potential accelerated approval using ORR primary endpoint.
Dr. Dominic Smethurst steps down as Chief Medical Officer, effective June 30, 2026.
Updated CRB-701 monotherapy data accepted for presentation at ASCO 2026 (May 29-June 2).
Company expects to report CRB-701 + Keytruda data in first-line HNSCC in Q4 2026; registrational study for HNSCC to start mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.